Media

April 9, 2025: Investigational Microbiotherapy MaaT033 Is Safe in Allo-HSCT Recipients – OncLive

Date : April 9, 2025

Lien vers le média

April 8, 2025: MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

April 9, 2025: MaaT Pharma reports safety interim analysis from trial of microbiome therapy – Clinical Trials Arena